Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/11/2026

1. RKLB
2. ACVA
3. RIOT
4. RPD
5. SPY
6. HIMS
7. NVDA
8. BBIO
9. FERG
10. CRWV

Go back to Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1223.46 -8.48 (0.69%)
Previous Close $1231.94    52 Week High $88.16 
Open $1230.65    52 Week Low $67.88 
Day High $1238.00    P/E 283.21 
Day Low $1210.01    EPS $4.32 
Volume 748,433